Early Rituximab Treatment Reduces Long-Term Disability in Patients With Aquaporin-4 Antibody–Positive Neuromyelitis Optica Spectrum Disorder
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Journal of Neurology, Neurosurgery, and Psychiatry
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Early rituximab treatment reduces long-term disability in aquaporin-4 antibody-positive neuromyelitis optica spectrum
J. Neurol. Neurosurg. Psychiatr. 2023 Jun 02;[EPub Ahead of Print], SY Park, YN Kwon, S Kim, SH Kim, JK Kim, JS Kim, TS Nam, YG Min, KS Park, JS Park, JM Seok, JJ Sung, E Sohn, KJ Shin, JH Shin, HY Shin, SI Oh, J Oh, BA Yoon, S Lee, JM Lee, HL Lee, K Choi, SY Huh, MJ Jang, JH Min, BJ Kim, SM KimFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.